Poor
Needs Improvement
Patient Risk:
Moderate
Summary
Many claims are broadly consistent with the provided label text (e.g., indication, mechanism at a high level, complex sleep behaviors, next-day impairment, and withdrawal effects). However, multiple statements are unsupported or not verifiable from the supplied label excerpts (e.g., eating while asleep, no-memory events, FDA strengthening/one-to-two-week typical duration, multiple specific withdrawal symptom types, gradual dose reduction, and manufacturer/origin/generics). Also, critical label categories (contraindications, boxed warnings, detailed dosing constraints) are not evaluated, making overall label alignment incomplete.
Category Scores
Accurate Statements
Ambien is indicated for short-term treatment of insomnia characterized by difficulties with sleep initiation.
1 INDICATIONS AND USAGE
Ambien contains zolpidem tartrate; zolpidem is a GABA-A receptor positive modulator of the imidazopyridine class.
11 DESCRIPTION; 12.1 Mechanism of Action
Zolpidem’s labeled mechanism includes binding to the benzodiazepine site of α1 subunit containing GABA-A receptors and inhibiting neuronal excitation via increased frequency of chloride channel opening.
12.1 Mechanism of Action
AMBIEN has CNS-depressant effects and next-day impairment risks (including drowsiness/sleepiness/reduced alertness the morning after therapy).
5.2 CNS-Depressant Effects and Next-Day Impairment
Complex sleep behaviors including sleep-walking and sleep-driving may occur; serious injuries including death may occur; discontinue immediately if a complex sleep behavior occurs.
WARNING: COMPLEX SLEEP BEHAVIORS (5 WARNINGS AND PRECAUTIONS)
Reports of withdrawal signs and symptoms can occur after rapid dose decrease or abrupt discontinuation of zolpidem.
5.9 Withdrawal Effects
Use the lowest effective dose for the patient.
2 DOSAGE AND ADMINISTRATION (2.1)
Unsupported Statements
Ambien is typically used for one to two weeks.
No supporting duration such as 'one to two weeks' appears in the provided label text/excerpts.
Ambien can cause unusual behaviors such as eating while asleep.
The provided label warning lists sleep-walking and sleep-driving and other activities while not fully awake; 'eating while asleep' is not explicitly stated in the supplied excerpts.
Sleep-walking, sleep-driving, and eating while asleep with Ambien can occur with no memory of the events.
The provided excerpt does not state 'no memory'; and 'eating while asleep' is not explicitly present in the excerpt.
The FDA has strengthened warnings regarding the risks of Ambien.
No statement about FDA strengthening warnings is present in the supplied label excerpts.
Withdrawal symptoms from abrupt Ambien discontinuation may include nausea.
The supplied 'Withdrawal Effects' excerpt does not list nausea as a withdrawal symptom.
Withdrawal symptoms from abrupt Ambien discontinuation may include vomiting.
The supplied 'Withdrawal Effects' excerpt does not list vomiting as a withdrawal symptom.
Withdrawal symptoms from abrupt Ambien discontinuation may include flushing.
The supplied 'Withdrawal Effects' excerpt does not list flushing as a withdrawal symptom.
Withdrawal symptoms from abrupt Ambien discontinuation may include dizziness.
The supplied 'Withdrawal Effects' excerpt does not list dizziness as a withdrawal symptom.
Withdrawal symptoms from abrupt Ambien discontinuation may include difficulty sleeping.
The supplied 'Withdrawal Effects' excerpt does not list difficulty sleeping as a withdrawal symptom.
Abrupt Ambien discontinuation can lead to difficulty sleeping as part of withdrawal symptoms.
The supplied 'Withdrawal Effects' excerpt does not support this specific symptom linkage.
Dose reduction of Ambien should be done gradually under the guidance of a healthcare professional.
The provided withdrawal excerpt does not include guidance on gradual dose reduction.
Ambien (zolpidem tartrate) was originally developed by Sanofi-Aventis.
No product origin/developer information is present in the supplied label excerpts.
Generic versions of Ambien are manufactured by various pharmaceutical companies.
No information about generic manufacturing entities is present in the supplied label excerpts.
Contradictions
Important Omissions
Contraindications (absolute safety limitations) were not assessed (e.g., the label text provided references contraindications in the complex sleep behavior warning).
Importance:
High
Boxed warning evaluation was not performed (no boxed-warning assessment included in the claims evaluation).
Importance:
High
Detailed dosage and administration constraints were not fully covered (e.g., sex-specific initial dosing; maximum total daily dose; single-dose/no readministration; requirement for at least 7–8 hours remaining).
Importance:
High
Drug interaction content was not evaluated (e.g., additive CNS-depression and related dose adjustments/recommendations referenced in the provided label excerpt).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some safety-relevant claims align with the provided excerpts (next-day impairment; complex sleep behaviors; withdrawal effects). However, multiple unsupported symptom-specific withdrawal claims and unsupported complex behavior details (eating while asleep; no-memory events) could mislead risk characterization. Additionally, omission of contraindications and boxed warning assessment limits label-compliance reliability for safety review.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Improvement
Primary Issue
Several claims are unsupported or not verifiable from the supplied label excerpts, and critical FDA-label categories (contraindications, boxed warnings, and detailed dosing constraints) were not evaluated.
Suggested Improvement
Limit claims to explicit label statements contained in the provided excerpts; remove unsupported items (e.g., eating while asleep, no-memory events, specific withdrawal symptom lists not present). Add assessments for contraindications, boxed warnings (if applicable in the label version), and detailed dosing/administration constraints (sex-specific dosing, max dose, timing, and single-dose/no re-administration).